rcca-header
Clinical Trials

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Type of Cancer
Genito-Urinary
Phase
Division (Location)
Hackensack, NJ
Study ID
NCT#
Brief Description
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.